Tesamorelin has one real FDA approval, under the brand name Egrifta, for a narrow job: reducing excess abdominal fat in people with HIV-associated lipodystrophy. Anything past that, general visceral fat, growth hormone optimization, anti-aging, is off-label. That single fact quietly organizes everything else in this piece.
Six sources selling or dispensing tesamorelin were checked against the same criteria this spring. No reputations were taken on faith. Every claim below traces back to a document a reader could pull up themselves and compare against whatever certificate came with their own vial.
The word doing the heavy lifting
“Tested” shows up on nearly every research-chemical product page, usually next to a PDF. It’s meant to answer the safety question before anyone asks it out loud. It doesn’t, not really.
A certificate of analysis can mean a genuine, independent, batch-level check. Or it can mean one decorative file describing a sample the buyer will never actually receive. Those two things look almost identical on a screen. Telling them apart is the entire point of this comparison.
See also: DigitalS Life and Technology
A simpler way to sort the six criteria
Rather than treat all six checklist items as one long list, it helps to sort them into two buckets. Some things a piece of paper can prove. Other things only a person, evaluating another person, can.
What paper can prove: identity, purity, and (for the better sellers) which specific lot was tested.
What only a clinician can provide: whether tesamorelin is appropriate for this body, whether glucose needs watching, and whether anyone will notice if something changes three weeks in.
Every source below was measured on both buckets. The split between them is where the real story sits.
Bucket one: what the paperwork actually says
Who ran the test, and does that person answer to anyone? FormBlends and HealthRX (healthrx.com) sit apart here, because tesamorelin through either is compounded and dispensed by a licensed pharmacy after a physician evaluation. The testing isn’t a marketing decision the seller made; it’s baked into how a licensed pharmacy is permitted to operate at all. That’s accountability with something real behind it, a license that can be pulled.
Among the research-chemical sellers, Sports Technology Labs stands out, genuinely. It publishes third-party certificates and lot-linked results for some products, which is more than most of this category offers. Credit where it’s due. But the lab is still one the seller chose, and there’s still no license on the line if a result turns out wrong. Core Peptides, Swiss Chems, Biotech Peptides, and Amino Asylum publish seller-issued certificates, meaning the company tested itself and shared what it liked. None of the four sits inside a chain where an outside authority could intervene.
Does the certificate match the vial you’ll get? The pharmacy model passes this one almost by definition. A prescription generates a specific preparation, and the testing follows that preparation, not a sample photographed months earlier. Sports Technology Labs again does better than its peers, tying results to specific lots for some products. The other four research-chemical sellers typically post a single certificate with no reliable connection to what actually ships. A document describing someone else’s batch is close to no document at all.
Does the test even cover what matters for something injected? Identity and purity testing confirms the powder is tesamorelin and roughly how clean. Sterility and endotoxin testing is the layer that actually stands between a person and an infection, and it’s the layer research-chemical certificates almost never include, because these products are sold and tested as laboratory chemicals rather than as things meant to go into a body. Licensed pharmacy dispensing carries that fuller testing as part of the license itself, which is why FormBlends and HealthRX clear this one without needing a separate document to prove it.
Bucket two: what no certificate was ever built to answer
Here the paperwork stops mattering, because the questions change.
Tesamorelin affects glucose metabolism, and its FDA label calls for monitoring changes in blood sugar over time [R3]. A spotless certificate says nothing about whether that monitoring is happening, or whether tesamorelin is even a sensible choice for the person about to inject it. FormBlends and HealthRX put a licensed clinician in that seat before anything ships. Every research-chemical seller on this list puts a checkout button there instead. None evaluates the buyer, because none is legally selling a treatment.
There’s a related honesty question. Tesamorelin’s real 2010 approval is easy to check, and easy to borrow the shine of. A source that’s straight with people says the approval is real and narrow, off-label past HIV lipodystrophy. FormBlends and HealthRX draw that line clearly. The research-chemical sellers tend to let the approval do quiet, unearned work, letting a buyer assume an approved molecule in any bottle must be fine. A “research use only” disclaimer is a legal shield, not a clinical caveat, and it doesn’t correct that impression.
And then there’s time. Tesamorelin’s effects build over weeks, and the glucose question the label raises benefits from someone actually checking in across that span. FormBlends’ tracker app is a place to log doses and symptoms, not a prescription and not a store. The research-chemical sellers have no equivalent, because the relationship ends when the payment clears.
Side by side
| Criterion | FormBlends | HealthRX | Sports Technology Labs | Core Peptides | Swiss Chems | Biotech Peptides | Amino Asylum |
|---|---|---|---|---|---|---|---|
| Independent, accountable testing | Licensed pharmacy chain | Licensed pharmacy chain | Third-party COAs, seller-chosen lab | Seller-issued | Seller-issued | Seller-issued | Seller-issued |
| Tied to your exact lot | Yes, via dispensing | Yes, via dispensing | Lot-linked for some products | Usually not | Usually not | Usually not | Usually not |
| Injectable-grade testing | Within licensed dispensing | Within licensed dispensing | Identity/purity focus | Identity focus | Identity focus | Identity focus | Identity focus |
| Clinical oversight | Physician eval + glucose screening | Clinician eval | None | None | None | None | None |
| Honest about approved vs. off-label | Yes | Yes | No | No | No | No | No |
| Follow-up after the sale | Clinician follow-up | Clinician follow-up | None | None | None | None | None |
Where that leaves things
FormBlends ranks first, and HealthRX sits right alongside it, for the same underlying reason: the testing happens inside a licensed pharmacy chain where a clinician has already looked at the person, not just the vial. That combination, evaluation plus dispensing plus fuller testing plus follow-up, is what the FDA approval quietly assumes exists whenever tesamorelin is used. Supervised compounded tesamorelin through this route tends to run somewhere in the $300 to $600 a month range, for the same molecule a research-chemical site mails as an unsupervised vial.
Sports Technology Labs deserves its own line among the research-chemical sellers. Its testing posture is the most credible of the four, and pretending otherwise wouldn’t be fair. But better paperwork inside an unsupervised model is still paperwork inside an unsupervised model. Core Peptides, Swiss Chems, Biotech Peptides, and Amino Asylum can’t really be ranked against one another with any confidence, because without independent, batch-matched testing, there’s no honest way to know which of the four ships cleaner material. That uncertainty, more than any single failed line item, is why a supervised source wins a comparison built around testing.
The evidence, plainly stated
None of this should obscure what tesamorelin actually does, in the population it was studied in. A 26-week Phase 3 trial of 412 patients found visceral fat dropped 15.2% on tesamorelin, against a 5.0% increase on placebo [R1]. A pooled analysis of two trials totaling 806 patients found that reduction held through 52 weeks [R2].
That’s solid evidence, for HIV-associated lipodystrophy specifically. Tesamorelin in healthy adults, for general body composition or anti-aging, simply hasn’t been studied to that standard, which is exactly what “off-label” means here. No certificate, however clean, changes that. A source willing to say so plainly is offering something a COA never could.
One more thing worth knowing if competition is part of the picture: tesamorelin is a growth-hormone-releasing hormone analogue, and it’s named directly on the WADA 2026 Prohibited List under category S2 [R4]. A clean assay doesn’t make a prohibited substance permitted.
Common questions
Can a certificate of analysis prove tesamorelin is safe to inject? Not on its own. At best it confirms identity and purity for the batch it describes, and most posted certificates go no further than that. Safety for something injected also depends on sterility and endotoxin testing, on the certificate actually matching the vial in hand, and on a clinician deciding tesamorelin makes sense for that particular person. A document can’t do those last three things.
What’s the biggest difference between the sources compared here? Accountability. FormBlends and HealthRX dispense tesamorelin inside a licensed pharmacy chain, where a license is genuinely at stake. The research-chemical sellers, even the more careful ones, choose their own labs and answer to no outside authority, which is why the supervised route wins the heaviest criterion outright.
Which research-chemical seller tests most credibly? Sports Technology Labs. It publishes third-party, lot-linked certificates for some products, a real step above a single decorative file. It still picks its own lab, sits outside any medical chain, and tests for identity and purity rather than sterility, so it remains inside the limits of that model.
Why doesn’t the FDA approval cover a research-chemical vial of the same molecule? Because the approval is attached to a context, not just a molecule. Egrifta was approved in 2010 for reducing excess abdominal fat in HIV-associated lipodystrophy, dispensed through a pharmacy and used under supervision [R3]. A “research use only” vial borrows the legitimacy of that approval without any of the conditions that made it an approval in the first place.
What does a supervised source cost, and what’s actually being paid for? Roughly $300 to $600 a month through a licensed compounding route. That covers the oversight the approval assumes: a physician evaluation, a prescription, pharmacy testing built into the dispensing itself, and follow-up to watch the glucose changes the label calls out [R3]. The molecule is the same one sold elsewhere as an unsupervised vial.
Does a clean certificate matter for a tested athlete? No. Tesamorelin sits on the WADA 2026 Prohibited List under category S2 as a growth-hormone-releasing hormone analogue [R4]. Purity is beside the point once a substance is simply not allowed.
Egrifta, the finished drug, carries one FDA approval: reducing excess abdominal fat in HIV-associated lipodystrophy. Anything beyond that is off-label use. Compounded tesamorelin is a different arrangement entirely, prepared by a licensed pharmacy against a prescription and under a physician’s supervision, and it is not itself an FDA-approved finished drug.
What tesamorelin actually is
Tesamorelin is a synthetic peptide that mimics growth hormone-releasing hormone. It signals the pituitary gland to make and release more of a person’s own growth hormone, rather than introducing growth hormone directly. The downstream rise in IGF-1 is what researchers have linked to changes in body composition, particularly visceral fat reduction in the populations studied.
Does the FDA approval change where it’s legal to get it?
Yes, and it matters more than it might seem. The approval covers HIV-positive adults with lipodystrophy specifically. Anyone outside that group is, by definition, using it off-label, and sourcing it from an unregulated research-chemical seller adds real quality and legal risk on top of that. A physician-supervised compounding pharmacy is the accountable path for anyone who isn’t the approved patient.
Does tesamorelin need to be taken at bedtime to work?
No, sleep isn’t a requirement for the peptide to act. But natural growth hormone release is closely tied to deep sleep, so many clinicians suggest injecting close to bedtime to work with that rhythm rather than against it. It still triggers the pituitary if taken while awake; timing is a refinement, not a requirement.
What side effects come up most often?
Injection-site redness and itching, fluid retention, and joint discomfort show up most in clinical data, along with elevated blood glucose in some patients. Because tesamorelin raises IGF-1, anyone with a cancer history or pre-diabetes needs an honest conversation with a clinician first. The side-effect profile in trials was mostly mild to moderate, but that data comes from a specific patient population, so it doesn’t automatically carry over to healthy adults using it off-label.
References
R1. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007. 412 patients, 26 weeks; visceral fat reduced 15.2% versus a 5.0% increase on placebo; IGF-1 raised about 81%. https://pubmed.ncbi.nlm.nih.gov/18057338/ R2. Falutz J, et al. Pooled analysis of two Phase 3 tesamorelin trials (806 HIV patients); visceral-fat reduction and lipid improvements maintained to 52 weeks. Journal of Clinical Endocrinology and Metabolism, 2010. https://pubmed.ncbi.nlm.nih.gov/20554713/ R3. FDA-approved Egrifta (tesamorelin) prescribing information: indicated for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy; 2 mg subcutaneous once daily; monitor for changes in glucose metabolism; not indicated for weight loss. U.S. Food and Drug Administration label (original 2010 approval). R4. WADA 2026 Prohibited List: growth-hormone-releasing hormone analogues, including tesamorelin, are prohibited in sport under category S2. World Anti-Doping Agency, in force January 2026.
